World Vaccines Market 2011-2021

• Publication date: June 2011

Do you want to know how the vaccines industry and market will develop from 2011? Our new report shows you potential revenues to 2021, discussing opportunities and prospects. Our report gives you market forecasts to 2021 for vaccines in human healthcare. You will find revenue predictions at total world, submarket, product, company and national levels. Through our research and analysis we aim to save you time and help in your decisions. ...

Do you want to know how the vaccines industry and market will develop from 2011? Our new report shows you potential revenues to 2021, discussing opportunities and prospects.

Our report gives you market forecasts to 2021 for vaccines in human healthcare. You will find revenue predictions at total world, submarket, product, company and national levels. Through our research and analysis we aim to save you time and help in your decisions.

You will see how products such as Prevnar, Pandemrix, Fluzone, Proquad/MMR-II/Varivax, Infanrix/Pediarix and Gardasil can perform to 2021. Our report shows revenue forecasts for leading vaccine brands.

In particular you will discover commercial prospects for GSK, Sanofi Pasteur, Merck & Co., Novartis and Pfizer, including revenue forecasts. We also discuss other vaccine producers.

Our report covers paediatric vaccines, influenza vaccines, other prophylactic vaccines, and therapeutic vaccines, with grouped forecasts. We discuss the R&D pipeline too, showing you where it is heading. 

We help you to assess the vaccine industry and market's strengths, weaknesses, trends and potential revenues to 2021. You will see what prospects the future holds.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Original analysis with revenues, growth rates, market shares, opinion and discussions 

Our report shows you revenue forecasts, growth rates, market shares, competitive analysis, a SWOT/STEP review, R&D developments and opinions from our survey. We include 190 tables and charts and four research interviews (shown in the accompanying lists).

World Vaccines Market 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:
• You will discover revenue predictions to 2021 for the world vaccines market and its main components, seeing where the highest revenue growth will occur
• You will see revenue forecasts to 2021 for leading vaccine products, with discussions of market potential and competition
• You will find revenue forecasts to 2021 for leading national markets for vaccines (US, Japan, UK,Germany, France, Spain, Italy, China, India, Russiaand Brazil)
• You will assess leading companies providing vaccines, discovering their activities, outlooks and revenue prospects
• You will investigate competition and opportunities influencing the industry and market from 2011 onwards
• You will see what will stimulate and restrain the industry and market from 2011
• You will review vaccine technologies, assessing R&D potential
• You will investigate vaccination needs and sales opportunities
• You will analyse opportunities and challenges for established companies and those seeking to enter the vaccines market
• You will receive four interviews with authorities on vaccines - from industry and other organisations.

That mix of quantitative and qualitative analysis sets our report apart. We tackle crucial questions in the vaccines industry and market, aiming to save you time and effort.

Order our report now to gain industry and market analysis for vaccines

Our report is for everybody interested in market analysis, product development, sales and marketing for vaccines. We give you predictions and answers. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6.
Pricing:
 
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs
 
 

Global Drug And Medication Industry

Table of Contents

1. Executive Summary
1.1 Vaccines Market Review
1.2 Contents of this Report
1.3 Research and Analysis Methods

2. Introduction to the Vaccines Market
2.1 Vaccines are a Public Health Success Story
2.2 The Rise of the Vaccines Market
2.2.1 Vaccines and the New Pharmaceutical Business Models
2.2.2 The First 'Blockbuster Vaccine'
2.2.3 Technological and Regulatory Improvements
2.2.4 A Highly Desirable Market to Enter
2.3 How Vaccines Work: The Immune System and Natural Immunity
2.3.1 Vaccines Create Artificial Immunity
2.4 Types of Vaccine
2.4.1 Live, Attenuated Vaccines
2.4.2 Recombinant Live Vaccines
2.4.3 Inactivated Vaccines
2.4.4 Toxoid Vaccines
2.4.5 Subunit Vaccines
2.4.6 Conjugate Vaccines
2.4.7 Recombinant Subunit Vaccines
2.4.8 DNA Vaccines
2.4.9 Recombinant Vector Vaccines
2.5 Vaccine-Preventable Diseases
2.5.1 Chickenpox and Shingles
2.5.2 Cholera
2.5.3 Diphtheria
2.5.4 Haemophilus Influenzae Type B (Hib) Diseases
2.5.5 Hepatitis A
2.5.6 Hepatitis B
2.5.7 Human Papillomavirus (HPV) - Cervical Cancer
2.5.8 Influenza
2.5.8.1 Seasonal Influenza
2.5.8.2 Pandemic Influenza
2.5.8.3 Influenza Vaccination
2.5.9 Japanese Encephalitis
2.5.10 Measles
2.5.11 Neisseria Meningitidis - meningococcal diseases
2.5.12 Mumps
2.5.13 Pertussis
2.5.14 Polio
2.5.15 Rabies
2.5.16 Rotavirus Infections
2.5.17 Rubella
2.5.18 Streptococcus pneumoniae infections
2.5.19 Tetanus
2.5.20 Tick-Borne Encephalitis
2.5.21 Tuberculosis
2.5.22 Typhoid
2.5.23 Yellow Fever
2.6 Future Vaccine-Preventable Diseases

3. The Global Vaccines Market 2011-2021
3.1 The Global Vaccines Market was Worth $27.6bn in 2010
3.2 The Paediatric Sector Still Dominates the Vaccines Market
3.3 Balance of the Vaccines Market, 2011-2021
3.4 Paediatric Vaccines 2011-2021
3.4.1 Paediatric Vaccines Market Forecast, 2011-2021
3.4.2 Proprietary Products are Driving Paediatric Vaccine Growth
3.4.3 Important Unmet Needs Remain in Paediatric Vaccines
3.4.4 New Paediatric Vaccines Face Regulatory and Market-Access Challenges
3.5 Influenza Vaccines 2011-2021
3.5.1 Influenza Vaccines Market Forecast, 2011-2021
3.5.2 Growth Drivers for the Influenza Market
3.5.3 The Importance of Pandemic Influenza
3.5.4 The Challenge of Sustaining Growth in the Influenza Sector
3.6 Other Prophylactic Vaccines 2011-2021
3.6.1 Other Prophylactic Vaccines Market Forecast, 2011-2021
3.6.2 The Hepatitis Submarket
3.6.3 Vaccines for Cancer Prophylaxis
3.6.4 Prospects for Adult Vaccination
3.7 Therapeutic Vaccines 2011-2021
3.7.1 Therapeutic Vaccines Market Forecast, 2011-2021
3.7.2 The Potential for Therapeutic Vaccines
3.7.3 Targets for Therapeutic Vaccine Development

4. Leading National Markets 2011-2021
4.1 The US, Europe and Japan are the Largest Markets for Vaccines
4.2 The US
4.2.1 The US Vaccine Market Forecast 2011-2021
4.2.2 The US National Vaccination Plan
4.2.3 Issues in the US Vaccines Market
4.3 The EU Top Five
4.3.1 The EU Top Five Vaccine Market Forecast 2011-2021
4.3.2 Distribution of the EU Market, 2010
4.3.3 The German Vaccines Market 2011-2021
4.3.4 The French Vaccines Market 2011-2021
4.3.5 The UK Vaccines Market 2011-2021
4.3.6 The Spanish Vaccines Market 2011-2021
4.3.7 The Italian Vaccines Market 2011-2021
4.4 Japan 
4.4.1 The Japanese Vaccines Market 2011-2021
4.5 BRIC Nations
4.5.1 BRIC Nations: Vaccines Market Forecast 2011-2021
4.5.2 The Brazilian Vaccines Market 2011-2021
4.5.3 The Russian Vaccines Market 2011-2021
4.5.4 The Indian Vaccines Market 2011-2021
4.5.5 The Chinese Vaccines Market 2011-2021
4.6 Rest of the World: Vaccines Market 2011-2021

5.Top Companies in the Global Vaccines Market 2011-2021
5.1 Five Companies Control Three Quarters of the Market
5.2 GlaxoSmithKline: The Leading Player in the Vaccines Market 
5.2.1 Vaccine Sales Forecast for GlaxoSmithKline, 2011-2021
5.2.2 GlaxoSmithKline Vaccine Portfolio and Pipeline, 2011
5.3 Sanofi Pasteur: The Largest Company Exclusively Dedicated to Human Vaccines
5.3.1 Vaccine Sales Forecast for Sanofi Pasteur, 2011-2021
5.3.2 Sanofi Pasteur Vaccine Portfolio and Pipeline, 2011
5.4 Merck & Co: The Former Market Leader
5.4.1 Vaccine Sales Forecast for Merck & Co., 2011-2021
5.4.2 Merck & Co. Vaccine Portfolio and Pipeline, 2011
5.5 Novartis: Technological Innovators in the Vaccines Sector
5.5.1 Vaccine Sales Forecast for Novartis, 2011-2021
5.5.2 Novartis Vaccine Portfolio and Pipeline, 2011
5.6 Pfizer: Late Entry into the Vaccines Market
5.6.1 Vaccine Sales Forecast for Pfizer, 2011-2021
5.6.2 Pfizer Vaccine Portfolio and Pipeline, 2011
5.7 Companies in the Vaccines Market, 2011-2021 Summary

6. Top 15 Vaccine Products 2011-2021
6.1 Prevnar Remains the Leading Franchise 
6.2 Prevnar (Pfizer)
6.2.1 Sales Forecast for Prevnar, 2011-2021
6.2.2 Competition for Prevnar, 2011-2021
6.3 Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines (GlaxoSmithKline)
6.3.1 Sales Forecast for Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines, 2011-2021
6.3.2 Competition for Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines, 2011-2021
6.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others (Sanofi-Aventis)
6.4.1 Sales Forecast for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2011-2021
6.4.2 Competition for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2011-2021
6.5 Proquad/M-M-R II/Varivax (Merck & Co.)
6.5.1 Sales Forecast for Proquad/M-M-R II/Varivax, 2011-2021
6.5.2 Competition for Proquad/M-M-R II/Varivax, 2011-2021
6.6 Focetria/Celtura/Other Pandemic Influenza Vaccines (Novartis)
6.6.1 Sales Forecast for Focetria/Celtura/Other Pandemic Influenza Vaccines, 2011-2021
6.6.2 Competition for Focetria/Celtura/Other Pandemic Influenza Vaccines, 2011-2021
6.7 Engerix/Fendrix/Havrix/Twinrix/Ambirix (GlaxoSmithKline)
6.7.1 Sales Forecast for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2011-2021
6.7.2 Competition for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2011-2021
6.8 Infanrix/Pediarix (GlaxoSmithKline)
6.8.1 Sales Forecast for Infanrix/Pediarix, 2011-2021
6.8.2 Competition for Infanrix/Pediarix, 2011-2021
6.9 Pediacel/Pentacel/Pentavac/Pentaxim/Act-HIB/Others (Sanofi Pasteur)
6.9.1 Sales Forecast for Pediacel/Pentacel/Pentavac/Pentaxim/Act-HIB/Others, 2011-2021
6.9.2 Competition for Pediacel/Pentacel/Pentavac/Pentaxim/Act-HIB/Others, 2011-2021
6.10 Gardasil (Merck & Co.)
6.10.1 Sales Forecast for Gardasil, 2011-2021
6.10.2 Competition for Gardasil, 2011-2021
6.11 Menactra (Sanofi Pasteur)
6.11.1 Sales Forecast for Menactra, 2011-2021
6.11.2 Competition for Menactra, 2011-2021
6.12 RotaTeq (Merck & Co.)
6.12.1 Sales Forecast for RotaTeq, 2011-2021
6.12.2 Competition for RotaTeq, 2011-2021
6.13 Adacel (Sanofi Pasteur)
6.13.1 Sales Forecast for Adacel 2011-2021
6.13.2 Competition for Adacel, 2011-2021
6.14 Cervarix (GlaxoSmithKline)
6.14.1 Sales Forecast for Cervarix 2011-2021
6.14.2 Competition for Cervarix, 2011-2021
6.15 Fluarix/Flulaval (GlaxoSmithKline)
6.15.1 Sales Forecast for Fluarix/Flulaval 2011-2021
6.15.2 Competition for Fluarix/Flulaval 2011-2021
6.16 Rotarix (GlaxoSmithKline)
6.16.1 Sales Forecast for Rotarix 2011-2021
6.16.2 Competition for Rotarix 2011-2021
6.17 Leading Products in the Vaccines Market, 2011-2021 Summary

7. Top R&D Pipeline Opportunities in the Vaccines Sector
7.1 Bexsero (Novartis)
7.2 Menhibrix (GlaxoSmithKline)
7.3 Hexaxim (Sanofi Pasteur)
7.4 GSK 2186877A (GlaxoSmithKline)
7.5 Mosquirix (GlaxoSmithKline)
7.6 Nimenrix (GlaxoSmithKline) 
7.7 Simplirix (GlaxoSmithKline) 
7.8 Varicella Zoster Virus Vaccine (GlaxoSmithKline) 
7.9 V 503 (Merck & Co.) 
7.10 Imojev/Chimerivax-JE (Sanofi Pasteur) 
7.11 HIV Vaccine (Sanofi Pasteur)
7.12 Adenovirus Type 4 Vaccine, Adenovirus Type 7 Vaccine (Teva) 
7.13 Astoprotimut (GlaxoSmithKline) 
7.14 NicVAX (GlaxoSmithKline)
7.15 VaccinOVAR (Menarini) 
7.16 Mitizax (ALK-Abello)
7.17 Ragweed Vaccine (ALK-Abello)
7.18 Grazax (ALK-Abello)
7.19 Stimuvax (Merck KGaA)
7.20 Cancer Vaccine (Otsuka)

8. The Vaccines Market: Qualitative Analysis
8.1 Strengths
8.1.1 Vaccines are Successful
8.1.2 Combination Vaccines Have Made Administration Easier
8.1.3 The Industry is Strongly Consolidated, Yet Has Strong Biotech Involvement
8.1.4 There is Global Multilateral Investment in Vaccines
8.1.5 Blockbuster Pricing, Blockbuster Branding
8.1.6 There is No Generic Competition
8.2 Weaknesses
8.2.1 High Entry Barriers
8.2.2 Manufacturing Capacity Problems are Inherent in the Vaccines Market
8.2.3 Storage and Supply Difficulties
8.2.4 Variable Demand
8.3 Opportunities
8.3.1 New Indications
8.3.2 Bioterrorism
8.3.3 New Delivery Systems
8.3.4 The Growth of the Emerging Economies
8.3.5 New Technologies
8.4 Threats
8.4.1 The Controversy Surrounding Vaccines
8.4.2 Lack of Public Education Regarding Vaccines
8.4.3 Threat to Prices

9. Expert Opinions from Our Survey
9.1 Interview with Richard de Souza, CEO, Archimedes Pharma, and Dr Alan Smith, VP, R&D, Archimedes Development Limited
9.1.1 On the Constraints of Developing a Seasonal Influenza Vaccine
9.1.2 On the Principal Drivers and Restraints in the Influenza Vaccine Market
9.1.3 On Vaccination Coverage Rates in the Mature and Emerging Markets
9.1.4 On the Important Pipeline Developments
9.1.5 On Vaccine Development in the Emerging Markets
9.1.6 On the Future of Influenza Vaccines
9.2 Interview with Catherine Ammon, Business Continuity Coordinator, World Health Organization,Switzerland
9.2.1 On the Preparedness of Countries to Tackle a Pandemic
9.2.2 On the Current and Future Vaccination Rates
9.2.3 On the Most Important Unmet Need for Influenza Management
9.2.4 On the Principal Drivers and Restraints in the Vaccine Market
9.2.5 On the Common Seasonal Influenza Vaccines used in Switzerland
9.2.6 On the Pipeline Vaccines with Most Promise
9.2.7 Other Comments on Influenza Vaccines and their Future
9.3 Interview with Professor David Bishai, MD, PhD, MPH, Department of Population, Family and Reproductive Health and International Health, Johns Hopkins University, USA
9.3.1 On Strategies for Presenting Vaccination to General Public
9.3.2 On Advantages and Disadvantages of MDVs and PFSs
9.3.3 On Pandemic Preparedness and Intervention
9.4 Interview with Wayne Rudolph, Vice President, Corporate Development, BiondVax Pharmaceuticals
9.4.1 On Unmet Needs in Influenza Management
9.4.2 On the Principal Drivers and Restraints in the Influenza Market
9.4.3 On the Burden of Influenza Epidemics to the Economy
9.4.4 On Current Market for Influenza Vaccines
9.4.5 On Vaccination Rates in Mature and Emerging Markets
9.4.6 On Vaccine Development Capacity in US, EU and Emerging Markets
9.4.7 On BiondVax and Challenges of Developing a Universal Flu Vaccine
9.4.8 On BiondVax Technology for Vaccine Manufacture
9.4.9 On Progress of BiondVax's Universal Flu Vaccine
9.4.10 On Pipeline Products from BiondVax
9.4.11 On Pipeline Products from Other Manufacturers
9.4.12 On Pandemic Preparedness

10. Conclusions
10.1 The Vaccines Market is One of the Pharmaceutical Industry's Major Success Stories
10.2 The Paediatric Sector Remains the Largest, but Other Sectors are Gaining in Significance
10.3 The Emerging Markets are Highly Important to the Sector
10.4 The Market is Highly Consolidated
10.5 Concluding Remarks

List of Tables

Table 3.1 Global Vaccines Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015
Table 3.2 Global Vaccines Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021 
Table 3.3 Sectors within the Vaccines Market: Description, Sales ($bn), Market Shares (%), 2010
Table 3.4 Global Vaccine Market Submarkets: Sales ($bn), AGR (%), CAGR (%), 2010-2015 
Table 3.5 Global Vaccine Market Submarkets: Sales ($bn), AGR (%), CAGR (%), 2016-2021 
Table 3.6 Paediatric Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015 
Table 3.7 Paediatric Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021 
Table 3.8 Leading Paediatric Vaccine Products: Indications, Sales ($bn), Market Shares (%), 2010
Table 3.9 Influenza Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015 
Table 3.10 Influenza Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021 
Table 3.11 Leading Influenza Vaccine Products, Indications, Sales ($bn), Market Shares (%), 2010
Table 3.12 Other Prophylactic Vaccines, Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015
Table 3.13 Other Prophylactic Vaccines, Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021
Table 3.14 Leading Other Prophylactic Vaccine Products, Indications, Sales ($bn), Market Shares (%), 2010
Table 3.15 Therapeutic Vaccines, Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015
Table 3.16 Therapeutic Vaccines, Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021
Table 4.1 National Market Forecasts: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.2 National Market Forecasts: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.3 US Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.4 US Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.5 Objectives and Achievements to Date of 1994 US National Vaccine Plan, 2011
Table 4.6 EU Top Five Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2021
Table 4.7 EU Top Five Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.8 EU Top Five, National Vaccines Markets: Sales ($bn), Market Shares (%), 2010
Table 4.9 German Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015
Table 4.10 German Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021
Table 4.11 French Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015
Table 4.12 French Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021
Table 4.13 UK Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015
Table 4.14 UK Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021
Table 4.15 Spanish Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015
Table 4.16 Spanish Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021
Table 4.17 Italian Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015
Table 4.18 Italian Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021
Table 4.19 Japanese Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.20 Japanese Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.21 BRIC Nations Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.22 BRIC Nations Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.23 Brazilian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), BRIC Market Shares (%), 2010-2015
Table 4.24 Brazilian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.25 Russian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.26 Russian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.27 Indian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.28 Indian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.29 Chinese Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.30 Chinese Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.31 Rest of the World Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.32 Rest of the World Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.1 Leading Companies in the Vaccines Market: Sales ($bn), Market Shares (%), 2010
Table 5.2 GlaxoSmithKline Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015
Table 5.3 GlaxoSmithKline Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021
Table 5.4 GlaxoSmithKline Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010
Table 5.5 GlaxoSmithKline Vaccines Pipeline, 2011 
Table 5.6 Sanofi Pasteur Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015
Table 5.7 Sanofi Pasteur Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021
Table 5.8 Sanofi Pasteur Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010
Table 5.9 Sanofi Pasteur Vaccines Pipeline, 2011 
Table 5.10 Merck & Co. Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015
Table 5.11 Merck & Co. Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021
Table 5.12 Merck & Co. Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010
Table 5.13 Merck & Co. Vaccines Pipeline, 2011
Table 5.14 Novartis Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015
Table 5.15 Novartis Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021
Table 5.16 Novartis Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010
Table 5.17 Novartis Vaccines Pipeline, 2011 
Table 5.18 Pfizer Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015
Table 5.19 Pfizer Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021
Table 5.20 Leading Companies in the Vaccines Market: Sales ($bn) AGR (%), CAGR (%), Market Share (%), 2010-2015
Table 5.21 Leading Companies in the Vaccines Market: Sales ($bn) AGR (%), CAGR (%), Market Share (%), 2016-2021 
Table 6.1 Prevnar: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.2 Prevnar: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.3 Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.4 Sanofi Pasteur Influenza Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.5 Sanofi Pasteur Influenza Vaccines: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.6 Proquad/M-M-R II/Varivax: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.7 Proquad/M-M-R II/ Varivax: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.8 Focetria/Celtura/Other Pandemic Influenza Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.9 GlaxoSmithKline Hepatitis Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.10 GlaxoSmithKline Hepatitis Vaccines: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.11 Infanrix/Pediarix: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.12 Infanrix/Pediarix: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.13 Sanofi Pasteur Paediatric Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.14 Sanofi Pasteur Paediatric Vaccines: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.15 Gardasil: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.16 Gardasil: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.17 Menactra: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.18 Menactra: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.19 RotaTeq: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.20 RotaTeq Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.21 Adacel: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.22 Adacel: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.23 Cervarix: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.24 Cervarix: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.25 Fluarix/Flulaval: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.26 Fluarix/Flulaval: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.27 Rotarix: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.28 Rotarix: Sales ($m) AGR (%), CAGR (%), 2016-2021
Table 6.29 Leading Products in the Vaccines Market: Sales ($m) AGR (%), CAGR (%), 2010-2015
Table 6.30 Leading Products in the Vaccines Market: Sales ($m) AGR (%), CAGR (%), 2016-2021 
Table 8.1 SWOT Analysis of the Vaccines Market, 2011-2021

List of Figures

Figure 3.1 Global Vaccines Market Forecast: Sales ($bn), 2010-2015 
Figure 3.2 Global Vaccines Market Forecast: Sales ($bn), 2016-2021 
Figure 3.3 Sectors within the Vaccines Market, Sales ($bn), Market Shares (%), 2010
Figure 3.4 Global Vaccine Market Submarkets: Sales ($bn), 2010-2015 
Figure 3.5 Global Vaccine Market Submarkets: Sales ($bn), 2016-2021 
Figure 3.6 Paediatric Market Forecast: Sales ($bn), 2010-2015 
Figure 3.7 Paediatric Market Forecast: Sales ($bn), 2016-2021 
Figure 3.8 Leading Paediatric Vaccine Products: Sales ($bn), Market Shares (%), 2010
Figure 3.9 Influenza Market Forecast: Sales ($bn), 2010-2015 
Figure 3.10 Influenza Market Forecast: Sales ($bn), 2016-2021 
Figure 3.11 Leading Influenza Vaccine Products, Sales ($bn), Market Shares (%), 2010
Figure 3.12 Other Prophylactic Vaccines Market Forecast: Sales ($bn), 2010-2015 
Figure 3.13 Other Prophylactic Vaccines Market Forecast: Sales ($bn), 2016-2021 
Figure 3.14 Leading Other Prophylactic Vaccine Products, Sales ($bn), Market Shares (%), 2010
Figure 3.15 Therapeutic Vaccines Market Forecast: Sales ($bn), 2010-2015 
Figure 3.16 Therapeutic Vaccines Market Forecast: Sales ($bn), 2016-2021 
Figure 4.1 Leading National Market Forecasts: Sales ($bn), 2010-2015 
Figure 4.2 Leading National Market Forecasts: Sales ($bn), 2016-2021 
Figure 4.3 US Vaccine Market: Sales ($bn), 2010-2015 
Figure 4.4 US Vaccine Market: Sales ($bn), 2016-2021 
Figure 4.5 EU Top Five Vaccine Market: Sales ($bn), 2010-2015 
Figure 4.6 EU Top Five Vaccine Market: Sales ($bn), 2016-2021 
Figure 4.7 EU Top Five, National Vaccines Markets: Sales ($bn), Market Shares (%), 2010
Figure 4.8 German Vaccines Market: Sales ($bn), 2010-2015
Figure 4.9 German Vaccines Market: Sales ($bn), 2016-2021
Figure 4.10 French Vaccines Market: Sales, ($bn), 2010-2015
Figure 4.11 French Vaccines Market: Sales, ($bn), 2016-2021
Figure 4.12 UK Vaccines Market: Sales ($bn), 2010-2015
Figure 4.13 UK Vaccines Market: Sales ($bn), 2016-2021
Figure 4.14 Spanish Vaccines Market: Sales ($bn), 2010-2015
Figure 4.15 Spanish Vaccines Market: Sales ($bn), 2016-2021
Figure 4.16 Italian Vaccines Market: Sales ($bn), 2010-2015
Figure 4.17 Italian Vaccines Market: Sales ($bn), 2016-2021
Figure 4.18 Japanese Vaccines Market: Sales ($bn), 2010-2015
Figure 4.19 Japanese Vaccines Market: Sales ($bn), 2016-2021
Figure 4.20 BRIC Nations: Vaccines Market ($bn), 2010-2015
Figure 4.21 BRIC Nations: Vaccines Market: Sales ($bn), 2016-2021
Figure 4.22 Brazilian Vaccines Market: Sales ($bn), 2010-2015
Figure 4.23 Brazilian Vaccines Market: Sales ($bn), 2016-2021
Figure 4.24 Russian Vaccines Market: Sales ($bn), 2010-2015
Figure 4.25 Russian Vaccines Market: Sales ($bn), 2016-2021
Figure 4.26 Indian Vaccines Market: Sales ($bn), 2010-2015
Figure 4.27 Indian Vaccines Market: Sales ($bn), 2016-2021
Figure 4.28 Chinese Vaccines Market: Sales ($bn), 2010-2015
Figure 4.29 Chinese Vaccines Market: Sales ($bn), 2016-2021
Figure 4.30 Rest of the World Vaccines Market: Sales ($bn), 2010-2015
Figure 4.31 Rest of the World Vaccines Market: Sales ($bn), 2016-2021
Figure 5.1 Leading Companies in the Vaccines Market: Sales ($bn), Market Shares (%), 2010
Figure 5.2 GlaxoSmithKline Vaccines: Sales ($bn), 2010-2015
Figure 5.3 GlaxoSmithKline Vaccines: Sales ($bn), 2016-2021
Figure 5.4 GlaxoSmithKline Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010
Figure 5.5 Sanofi Pasteur Vaccines: Sales ($bn), 2010-2015
Figure 5.6 Sanofi Pasteur Vaccines: Sales ($bn), 2016-2021
Figure 5.7 Sanofi Pasteur Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010
Figure 5.8 Merck & Co. Vaccines: Sales ($bn), 2010-2015
Figure 5.9 Merck & Co. Vaccines: Sales ($bn), 2016-2021
Figure 5.10 Merck & Co. Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010
Figure 5.11 Novartis Vaccines: Sales ($bn), 2010-2015
Figure 5.12 Novartis Vaccines: Sales ($bn), 2016-2021
Figure 5.13 Novartis Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010
Figure 5.14 Pfizer Vaccines: Sales ($bn), 2010-2015
Figure 5.15 Pfizer Vaccines: Sales ($bn), 2016-2021
Figure 6.1 Prevnar: Sales ($m), 2010-2015
Figure 6.2 Prevnar: Sales ($m), 2016-2021
Figure 6.3 Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines: Sales ($m), 2010-2015
Figure 6.4 Sanofi Pasteur Influenza Vaccines: Sales ($m), 2010-2015
Figure 6.5 Sanofi Pasteur Influenza Vaccines Sales ($m), 2016-2021
Figure 6.6 Proquad/M-M-R II/Varivax Sales ($m), 2010-2015
Figure 6.7 Proquad/M-M-R II/Varivax: Sales ($m), 2016-2021
Figure 6.8 Focetria/Celtura/Other Pandemic Influenza Vaccines: Sales ($m), 2010-2015
Figure 6.9 GlaxoSmithKline Hepatitis Vaccines: Sales ($m), 2010-2015
Figure 6.10 GlaxoSmithKline Hepatitis Vaccines: Sales ($m), 2016-2021
Figure 6.11 Infanrix/Pediarix: Sales ($m), 2010-2015
Figure 6.12 Infanrix/Pediarix: Sales ($m), 2016-2021
Figure 6.13 Sanofi Pasteur Paediatric Vaccines: Sales ($m), 2010-2015
Figure 6.14 Sanofi Pasteur Paediatric Vaccines: Sales ($m), 2016-2021
Figure 6.15 Gardasil: Sales ($m), 2010-2015
Figure 6.16 Gardasil: Sales ($m), 2016-2021
Figure 6.17 Menactra: Sales ($m), 2010-2015
Figure 6.18 Menactra: Sales ($m), 2016-2021
Figure 6.19 RotaTeq: Sales ($m), 2010-2015
Figure 6.20 RotaTeq: Sales ($m), 2016-2021
Figure 6.21 Adacel Sales ($m), 2010-2015
Figure 6.22 Adacel: Sales ($m), 2016-2021
Figure 6.23 Cervarix: Sales ($m), 2010-2015
Figure 6.24 Cervarix: Sales ($m), 2016-2021
Figure 6.25 Fluarix/Flulaval: Sales ($m), 2010-2015
Figure 6.26 Fluarix/Flulaval: Sales ($m), 2016-2021
Figure 6.27 Rotarix: Sales ($m), 2010-2015
Figure 6.28 Rotarix: Sales ($m), 2016-2021
 
Companies Listed

Abbott
Acambis
Advisory Committee on Immunization Practices (ACIP) 
ALK-Abello
AlphaVax
American Home Products 
AstraZeneca
Avant Immunotherapeutics
Bavarian Nordic
Bayer Schering 
Baxter
Bharat Biotech
Biken Japan 
Bill and Melinda Gates Foundation
Binnopharm
Biocryst
Biogen Idec
Biological E
Bio-Manguinhos
Biomira
Butantan
Cell Control
Celltech
Chemo-Sero-Therapeutic Research Institute
China National Biotec Group 
Chinese Academy of Medical Sciences
Chiron
Coley Pharmaceutical
Commonwealth Serum Laboratories
Corixa
Crucell
CSL Biotherapies
Cytos
Daiichi Sankyo
Dendreon
Denka Seiken Company
European Medicines Agency (EMEA/EMA)
European Vaccine Manufacturers (EVM)
Evans Medica
Food and Drug Administration (US FDA) 
Fuso
GAVI 
GlaxoSmithKline
Global Alliance for Vaccines and Immunisation
Hualan Biological Engineering 
ID Biomedical
Institute for Genetic Research
Institute for Genomic Research 
Intercell
Italian National Health Service
Jiangsu Walvax Biotech Company
Johnson & Johnson 
Kitasato Institute
Lederle
Ludwig Institute for Cancer Research
Medeva
Medicare
MedImmune
Medirace
Menarini
Merck & Co.
Merck KGaA
Ministry of Health, Labour and Welfare (Japan)
Nabi Biopharmaceuticals
National Health Service (NHS)
National Institutes of Health (NIH)
National Institute for Clinical Excellence (NICE)
Novartis
Novavax
Oncothyreon
OncoTherapy Science
Otsuka
Oxford University
Pfizer
PowderJect
Protein Sciences
Ranbaxy
Roche
ROVI Pharmaceuticals
Sandoz
Sanofi
Sanofi Pasteur
Serum Institute
Shanghai Institute of Biological Sciences
Shantha Biotech 
Sinovac
Spanish Ministry of Health
Takeda
Thai Ministry of Public Health
UNICEF
UK Joint Committee on Vaccination and Immunisation
University of Massachusetts Medical School 
University of Queensland
University Hospital of Tubingen
US Advisory Committee on Immunization Practices
US Army
US Centers for Disease Control and Prevention
US Department of Defense
US Department of Health and Human Services 
Vaccine Manufacturers Association (India)
Vaxdesign
VaxInnate
VIVALis
Walter Reed Army Institute 
Wellcome Trust 
World Health Organization (WHO)
Wyeth
Zhejiang Tianyuan